Increase in Serum Transthyretin After Tafamidis Is Associated With Improved Survival in Transthyretin Amyloid Cardiomyopathy - PubMed
2 days ago
- #cardiomyopathy
- #tafamidis
- #transthyretin amyloidosis
- Increase in serum transthyretin levels after tafamidis treatment is linked to better survival in transthyretin amyloid cardiomyopathy.
- The study highlights the potential benefits of tafamidis in managing transthyretin amyloidosis, particularly in cardiac involvement.
- Authors disclose various financial relationships with pharmaceutical companies, including Pfizer, Alnylam, BridgeBio, and AstraZeneca.
- Funding for the research includes support from NIH grants R01HL177670 and R01AG081582.